Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2019-11-25 16:32:32
Reporting Period:
Accepted Time:
2019-11-25 16:32:32
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
1609809 Seres Therapeutics Inc. MCRB Pharmaceutical Preparations (2834) 274326290
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1770404 Marcus Chapman C/o Seres Therapeutics, Inc.
200 Sidney Street
Cambridge MA 02139
See Remarks No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-11-01 12,000 $0.00 12,000 No 4 M Direct
Common Stock Disposition 2019-11-22 3,400 $3.91 8,600 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2019-11-01 12,000 $0.00 12,000 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 M Direct
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan, dated June 15, 2017.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.90 to $3.93. The reporting person undertakes to provide Seres Therapeutics, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
  4. The restricted stock units vested in full on November 1, 2019.